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Abstract
Background: Understanding the molecular/cellular underpinnings of diffuse malignant peritoneal mesothelioma
(DMPM), a fatal malignancy with limited therapeutic options, is of utmost importance for the fruitful management
of the disease. In this context, we previously found that telomerase activity (TA), which accounts for the limitless
proliferative potential of cancer cells, is prognostic for disease relapse and cancer-related death in DMPM patients.
Consequently, the identification of factors involved in telomerase activation/regulation may pave the way towards
the development of novel therapeutic interventions for the disease. Here, the capability of miR-380-5p, a microRNA
negligibly expressed in telomerase-positive DMPM clinical specimens, to interfere with telomerase-mediated
telomere maintenance and, hence, with cancer cell growth was assessed on preclinical models of DMPM.
Methods: DMPM cells were transfected with a miR-380-5p synthetic precursor, and the effects of miRNA
replacement were evaluated in terms of growing capability, induction of apoptosis and interference with TA.
Reiterated weekly transfections were also performed in order to analyse the phenotype arising upon prolonged
miR-380-5p reconstitution in DMPM cells.
Results: The ectopic expression of miR-380-5p elicited a remarkable inhibition of TA and resulted in DMPM cell
growth impairment and apoptosis induction. In particular, we demonstrated for the first time that these effects
were the result of a molecular circuitry converging on telomerase associated protein 1 (TEP1), where the miRNA
was able to target the gene both directly in unconventional targeting modality and indirectly via p53 accumulation
consequent to miRNA-mediated downregulation of testis-specific protein, Y-encoded-like 5 gene. Moreover, miR-
380-5p did not cause telomere attrition and cell growth arrest in long-term DMPM transfectants, which in turn
showed slightly elongated telomeres and molecular features (e.g. c-circle DNA and reduced expression levels of
chromatin remodeler ATRX) resembling an alternative lengthening of telomeres (ALT) phenotype.
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Conclusions: miR-380-5p interferes with TA in DMPM cells by targeting TEP1. Notably, in the long-term setting,
miR-380-5p-mediated impairment of TA did not result in telomere attrition. Instead, a phenotype reminiscent of
ALT emerged in DMPM cells as possible compensatory pathway that safeguards DMPM cell growth, an event that
may be regarded as a potential resistance mechanism to anticancer therapies based on telomerase inhibitors.
Keywords: Alternative lengthening of telomeres, Diffuse malignant peritoneal mesothelioma, miRNA, Telomerase
associated protein 1, Telomere maintenance mechanisms, Testis-specific protein, Y-encoded-like 5
Background
Telomeres are guanine-rich DNA (5′-TTAGGG-3′)
repeats and associated proteins located at the very end
of eukaryotic chromosomes [1]. Telomere maintenance
mechanisms (TMM) endow tumour cells with replicative
immortality—a hallmark of cancer—in that they coun-
teract the progressive telomere attrition, which occurs
during each cell replication cycle and limits normal cell
divisions to a finite number [1].
Telomerase activity (TA) and the alternative lengthen-
ing of telomere (ALT) pathway are the only two TMM
yet identified in human cancers [1]. Telomerase is a
reverse transcriptase consisting of two main subunits: the
long non-coding RNA molecule TERC, which contains
the template sequence for the synthesis of telomeric
DNA, and the catalytic protein portion telomerase reverse
transcriptase (TERT) [1]. The two subunits associate with
distinct ancillary proteins that are necessary for the
correct assembly, stability, mode of operation and intracel-
lular trafficking of the holoenzyme (Fig. 1a) [1].
TA is the most frequently activated TMM in human
tumours, whereas ALT is prevalently activated in mesen-
chymal tumours (e.g. osteosarcomas, soft-tissue sarco-
mas) and, less frequently, in carcinomas (breast, gastric,
ovarian cancers), malignant melanomas and neuroendo-
crine pancreatic cancers [2].
Although ALT is thought to be driven by homologous
recombination, the knowledge of the molecular mecha-
nisms underpinning it in cancers is still fragmentary.
Consequently, ALT tumours are generally defined accord-
ing to a combination of two or more markers [2], including
i) the presence of long and heterogeneous telomeres and of
extrachromosomal telomeric DNA (e.g. c-circle DNA); ii)
the occurrence of spontaneous and telomeric-localized
DNA damage; iii) the presence of ALT-associated promye-
locytic leukaemia (PML) bodies (APB), a subset of PML
nuclear bodies containing telomeric DNA and telomere-
associated proteins/DNA repair factors; iv) the absence of
TA and v) the loss/reduced expression and/or mutations of
the chromatin remodeler ATRX [3, 4].
Translational studies have revealed that TMM can
variably affect the outcome of patients as a function of
tumour type. For instance, it has been demonstrated that
patients with ALT-positive, high-grade glioblastoma
multiforme have significantly longer survival than those
with ALT-negative tumours, whereas a poor prognosis
characterizes patients with ALT- and TA-positive osteo-
sarcomas with respect to patients with tumours that
apparently lack of TMM [1]. In addition, ALT and TA have
been associated with an unfavourable disease outcome in
liposarcomas, although a worse prognosis, in terms of
increased mortality, was observed for patients with ALT
tumours [1]. Moreover, TA was found to be prognostic for
tumour relapse and cancer-related death in diffuse malig-
nant peritoneal mesothelioma (DMPM) as well as for
cancer-related death in malignant peripheral nerve sheath
tumour patients, whereas ALT failed to significantly affect
clinical outcome in both cancer types [5, 6].
The fragmentary information currently available on
ALT at molecular level has thus far hampered the develop-
ment of ALT-specific therapeutic interventions, whereas
distinct anti-telomerase therapeutic approaches have been
developed and presently tested in clinical trials [7]. This
evidence suggests that improving the knowledge of
the molecular mechanisms subtending the activation/
regulation of ALT vs. telomerase and vice versa dur-
ing cancer development and progression is of utmost
importance to better understand the implications of
telomere biology and of telomerase-based therapeutic
approaches in clinical tumours.
MicroRNAs (miRNAs) are small non-coding RNAs
that negatively regulate gene expression through the
RNA interference (RNAi) pathway [8]. They are involved
in the control of several biological processes, and their
deregulated expression may contribute to diverse patho-
logical conditions, including cancer development and
progression [8]. Accumulating evidence suggests that,
compared to normal counterparts, tumour tissues show
typical miRNA signatures, which may represent useful
diagnostic markers. Moreover, changes in the expression
levels of specific miRNAs have been documented to be
predictive of prognosis or treatment response in cancer
patients [9].
Deregulated miRNA levels trigger a global perturbation
in the expression or function of target genes having pro-
or anti-tumour properties. This implies that a specific
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miRNA may exert oncogenic or tumour-suppressive
functions depending on the cell/tissue context and the
presence of its target genes [1]. Consequently, attempts to
modify the expression of selected miRNAs currently
represent an intriguing approach to defeat cancer as well
as to ameliorate the response of tumour cells to standard
anticancer therapies [8, 9].
Owing to their role in cancer, miRNAs may plausibly
contribute to the establishment and/or regulation of
TMM. Here, we show that miR-380-5p, a miRNA that is
negligibly expressed in telomerase-positive DMPM tissues
and cell lines, interferes with telomerase-dependent
telomere maintenance. In particular, the ectopic miR-380-5p
expression in DMPM cells results in TA inhibition through
Fig. 1 miR-380-5p impairs the growth of DMPM cells and inhibits TA by downregulating TEP1. a The drawing schematically shows the minimal
components TERT (telomerase reverse transcriptase) and TERC (telomerase RNA component) of telomerase associated with telomeric DNA and
with some ancillary proteins involved in the stabilization (DKC1: dyskerin pseudouridine synthase 1), proper functioning (TEP1, telomerase associated
protein 1) and intra-nuclear localization (WRAP53, WD repeat containing antisense to TP53) of the enzyme. b Basal miR-380-5p expression levels in
normal, non-immortalized mesothelial (MES-F) cells, in TA-positive DMPM (STO, MP8, MP4) and lung adenocarcinma (A549) cells as well as in the TA-
negative (ALT-positive) U-2 Os cell line (Log10(RQ) with respect to MES-F cells; mean values ± s.d.). c Time-course assessment of miR-380-5p expression
levels in preNeg- and miR-380-5p-transfected STO cells (Log10(RQ) with respect to non transfected (NT) cells; mean value ± s.d.). d Growth curves of NT,
preNeg- and miR-380-5p-transfected STO cells (number of growing cells; mean value ± s.d.); *P < 0.05; **P < 0.02 in miR-380 vs. preNeg. e Quantification
of TA (arbitrary units (a.u.); mean values ± s.d.); **P < 0.01 vs. preNeg-transfected cells. f Representative immunoblotting showing the amounts of p53,
p21waf1 and of apoptotic markers upon a 96-h transfection of STO cells with preNeg or miR-380-5p. Cropped images of selected proteins are shown.
g TEP1 expression levels in miR-380-5p- vs. preNeg-transfected DMPM and U-2 Os cells (percentage of gene expression inhibition; mean values ± s.d.).
h Representative immunoblotting (cropped images of selected proteins are shown) and quantification of TEP1 amounts in preNeg- and miR-380-5p-
transfected DMPM and U-2 Os cells. Data have been reported as percentage of protein amounts in miR-380-5p- vs. preNeg-transfected DMPM and U-2
Os cells (mean values ± s.d.)
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a molecular circuitry involving the downregulation of TEP1
and TSPYL5, which we demonstrate for the first time to be
direct targets of the miRNA. In addition, we found that miR-
380-5p may lead to the emergence of molecular features
reminiscent of an ALT phenotpye, as long-term DMPM cell
cultures expressing the miRNA were characterized by re-
duced expression levels of ATRX and increased levels of
telomeric c-circle DNA.
Methods
Reagents and chemicals
miR-380-5p synthetic precursor (pre-miR-380-5p) and
the negative control oligomer (preNeg) were purchased
as Pre-miR™ miRNA precursor molecules (Thermo
Fisher Scientific). miR-380-5p inhibitor (LNA380) and
the relative control oligomer (LNANeg) were purchased
as miRCURY LNA™ microRNA Inhibitors (Exiqon A/S,
Vedbaek, Denmark). Commercially available small
interfering RNAs (siRNA) targeting TEP1 (siTEP1),
TSPYL5 (siTSPYL5), p53 (sip53) and control siRNAs
(siCTR) were obtained from Santa Cruz Biotechnology
Inc. (Dallas, TX, USA). Target protector oligomers were
purchased as miScript Target Protectors (Qiagen,
Hilden, Germany). Doxorubicin hydrochloride was
from Sigma-Aldrich (Milano, Italy). The reagents were
dissolved in nuclease-free, sterile water, stored at
−20 °C and diluted at the appropriate working con-
centration just before use.
Cell lines and transfection procedures
DMPM (STO, MP8 and MP4) cells [10], A549 lung
cancer cells (ATCC®-CCL-185™), U-2 Os osteosarcoma
cells (ATCC® HTB-96™) and human adult mesothelial
MES-F cells (Zen-Bio Inc., Research Triangle Park,
NC) were maintained in the logarithmic growth phase
in Dulbecco’s modified Eagle’s (DMEM), DMEM-F12
(Lonza Milano S.r.l, Treviglio, Italy) and MSO-1 (Zen-
Bio Inc.) media, respectively, supplemented with foetal
bovine serum, at 37 °C in a humidified incubator at
5% CO2. Cells were periodically monitored for DNA
profile by short tandem repeats analysis using the
AmpFISTR Identifiler PCR amplification kit (Thermo
Fisher Scientific, Monza, Italy).
For the transfection procedures, cells seeded at the ap-
propriate density and allowed to attach for 72 h (DMPM
cells) or 24 h (A549, U-2 Os, MES-F) were incubated
with Lipofectamine-2000TM (Thermo Fisher) in Opti-
MEM I (Thermo Fisher). After 15 min at r.t., lipid-
treated cells were added with Opti-MEM I medium
containing the oligomers at the final concentrations of
20 nM (pre-miR-380-5p; preNeg), 100 nM (LNA380;
LNA-Neg) or 50 nM (siTEP1, siTSPYL5 and sip53), and
incubated for 4 h at 37 °C. For target protection experi-
ments, 100 nM of custom designed TEP1 or TSPYL5
target protectors was transfected in combination with
miR-380-5p precursor or preNeg, under the same trans-
fection conditions described above. Cells were then har-
vested according to the timeline of each experiment and
subsequently analysed. For the long-term assessment of
miR-380-5p effects, the transfection procedure was reit-
erated every 7 days, up to 3 months. For the assessment
of cell growth, cells were collected at different time
intervals and their number and viability were evaluated
by a dye exclusion test (0.4% Trypan Blue Solution, Sigma-
Aldrich) using a TC20TM automated cell counter (Bio-Rad
Laboratories S.r.l., Segrate, Italy). For doxorubicin-based
experiments, cells were treated with 3 μg/ml of the drug,
preliminary defined as a sub-toxic concentration, 24 h
after the transfection with sip53 or siCTR and cultured for
additional 48 h. Non-transfected (NT) cells were run in
parallel.
Analysis of miR-380-5p and gene expression levels
Total RNA was isolated using Qiagen RNeasy Mini kit
(Qiagen, Hilden, Germany) and digested with 20 U
RNase-free DNase. miR-380-5p expression levels were
analysed using TaqMan® microRNA Assay (P/N 4427975,
Applied Biosystems, Foster City, CA, USA), according to
the manufacturer’s instruction. Gene expression analysis
was carried on randomly primed total RNA using the
High Capacity cDNA Reverse Transcription kit (Applied
Biosystems). Each gene was amplified using the following
TaqMan® Gene expression assays (Applied Biosystems):
ATRX (Hs00230877); TEP1 (Hs00200091); and TSPYL5
(Hs00603217). Amplifications were run on the 7900HT
Fast Real-Time PCR System (Applied Biosystems). Data
were analysed by SDS 2.2.2 software (Applied Biosystems)
and, if not otherwise specified, reported as relative
quantity (RQ or Log10(RQ)) with respect to a calibrator
sample using the 2−ΔΔCt method, where Ct represents the
threshold cycle. RNU48 snRNA (P/N 4427975) and RNaseP
(P/N 4316844) were used as normalisers during the analysis
of miR-380-5p and mRNAs expression levels, respectively.
Western immunoblotting
Forty micrograms of total protein extracts prepared
according to standard methods was fractioned by SDS-
PAGE, transferred onto nitrocellulose filters and incu-
bated o.n. with primary antibodies: mouse monoclonal
antibodies raised against β–actin, PAX8, TNKS, WRAP53;
rabbit polyclonal antibodies raised against H2AX, γ-
H2AX (S139), p21Waf1, POT1, PRKCA (Y124), TEP1 and
a goat polyclonal antibody raised against TNKS2 (Abcam,
Cambridge, UK); rabbit polyclonal antibodies raised
against TERF2, TSPYL5 and the mouse monoclonal raised
against p53 (Santa Cruz Biotechnology); rabbit polyclonal
antibodies raised against PARP1 and CPP32 (Cell Signal-
ing Technology, Danvers, MA, USA). The filters were
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then probed with secondary peroxidase-linked whole anti-
bodies (GE Healthcare, Milano, Italy) and detected by
Novex® ECL HRP Chemiluminescent detection system
(Thermo Fisher). Filters were then subjected to autoradi-
ography. β-Actin (ACTB) was used on each blot to ensure
equal protein loading.
Luciferase assay
To test the effect of miR-380-5p on its predicted target,
the pEZX-MT05 vector (GeneCopoeia Inc., Rockville,
MD, USA), hosting the whole 3′-UTR of TSPYL5
(GeneBank accession NM_033512.2) downstream the re-
porter Gaussia luciferase (GLuc) gene and containing a
second reporter gene (Secreted Alkaline Phosphatase,
SEAP) for transfection-normalization, was used. A mu-
tated reporter construct (del43-54) characterized by the
deletion of the seed region within the predicted miR-380-
5p binding site was generated using the QuikChange II
site-directed mutagenesis kit (Agilent Technologies Italia
S.p.A., Cernusco S/N, Italy), according to the manufac-
turer’s instructions, in the presence of the following
primer pair: F_5′-ctagctgcatcacttatcagtggtttcatctgtatctctc-
3′ and R_5′-gagagatacagatgaaaccactgataagtgatgcagctag-3′.
To assess the luciferase activity, STO cells were trans-
fected with gene reporter constructs, in the presence or
absence of pre-miR-380-5p or preNeg using Lipofectami-
ne3000TM (Thermo Fisher), according to the manufac-
turer’s protocol and incubated at 37 °C. GLuc and SEAP
enzymatic activities were then measured in the culture
media collected at 24, 48 and 72 h after transfection using
the Secrete-PairTM Dual Luminescence Assay Kit (Gene-
Copoeia Inc.), according to manufacturer’s instructions.
For the co-transfection experiments, 24 h after the
transfection with pEZX-MT05 and pre-miR-380-5p, cells
were transfected with miRNA inhibitors (LNA380 or
LNA-Neg) and assessed for luciferase activity 48 h later.
PEZX-MT05-expressing cells transfected with single
oligomers (preNeg, pre-miR-380-5p, LNA-Neg or LNA380)
were run in parallel.
Target enrichment analysis
Cells (2 × 107) were suspended in RIP buffer (10 mM
Tris, pH 7.5; 10 mM KCl; 2 mM MgCl2; 1 mM DTT,
100 U/ml RNase inhibitor and a protease inhibitor
mixture) for 15 min, homogenized with a Dounce
homogenizer and centrifuged at 13,000 rpm at 4 °C for
10 min. Five percent of each solution was set apart to be
used as control (Input) for the RT-PCR amplification.
The remaining was incubated with IgGA/IgG-coated
beads for 1 h at r.t. and centrifuged at 13,000 rpm
for 1 min. The supernatants were then mixed with
5 μg of a rat monoclonal anti-human Ago2 antibody
(Sigma-Aldrich) and a rabbit polyclonal human IgG
(Abcam). After an overnight incubation at 4 °C, samples
were re-incubated with IgGA/IgG-coated beads for 1 h at
4 °C, centrifugated at 2500 rpm for 1 min and washed
twice with RIP buffer containing 150 mM NaCl and 0.5%
Nonidet P-40 and once with buffer containing 400 mM
NaCl and 0.5% Nonidet P-40. Finally, the RNA was ex-
tracted from the AGO2- and IgG-IP complexes using
TRIzol (Thermo Fisher), according to the manufacturer’s
instruction. The enrichment for miRNA binding sites was
evaluated by RT-PCR using the High Capacity cDNA Re-
verse Transcription kit (Applied Biosystems). Site #1 was
amplified by one-step PCR at 95 °C for 5 min followed by
33 cycles [95 °C 45 s; 57 °C 30 s; 72 °C 30 s] and 72 °C for
5 min using the following forward (5′-cagtccccaaagaggaa-
caa-3′) and reverse (5′-tcatggtccggggtttatta-3′) primer
pair. The fragment corresponding to site #2 was first amp-
lified at 95 °C for 5 min followed by 20 cycles [95 °C 45 s;
57 °C 30 s; 72 °C 30 s] using the following forward (5′-
cgtaccttggccttcaatgt-3′) and reverse (5′-cagagaccctgaccaca
cct-3′) primer pair. One tenth of the amplification reac-
tion was then re-amplified for 22 additional cycles under
the same conditions followed by an elongation step at
72 °C for 5 min. The reaction products were resolved
by agarose gel electrophoresis. Images were captured by
UVIDOC HD5 (UVITec Ltd., Cambridge, UK) and
subjected to densitometric analysis using ImageJ 1.46r.
The fold-enrichment was calculated after normalization
towards Input RNA as the ratio between the mRNA
levels detected in AGO2-IP or IgG-IP samples and
the mRNA levels in IgG-IP sample from non trans-
fected cells.
Assessment of telomerase activity, telomere length and
C-circle DNA levels
Telomerase activity was measured on 1 μg of protein by
the Telomeric Repeat Amplification protocol (TRAP)
using the (TRAPeze® kit; Merck S.p.A., Vimodrone, Italy)
and quantified according to the manufacturer’s instruc-
tions [6]. Telomere length analysis was carried out on
Rsa I/Hinf I-digested total DNA upon pulsed-field gel
electrophoresis and southern blot, as previously de-
scribed [6]. DNA-Hind III digest (Bio-Rad Laboratories)
was used for size determination of telomere restriction
fragments (TRF). Mean telomere length (mTL) was
calculated by densitometric analysis (ImageJ 1.46r) as re-
ported by Kimura et al. [11]. C-circle DNA levels were
assessed by the CC assay (CCA) [12]. Briefly, genomic
DNA was incubated at 30 °C for 8 h in the presence or
absence of 7.5 U of φ29 DNA polymerase (New England
BioLabs), heat-inactivated at 65 °C for 20 min and dot-
blotted. After UV-cross-linking, filters were hybridized
with a 32P-(CCCTAA)3 probe using PerfectHyb Plus
hybridization buffer (Sigma-Aldrich), washed, exposed to
a PhosphoImager screen and scanned on a Typhoon
8600 Variable Mode Imager (GE Healthcare). Signal
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intensity was quantified using the VisionWorks LS soft-
ware (UVP Ltd.). Genomic DNA from ALT-positive U-2
Os and telomerase-positive HeLa cells was included as
positive and negative control, respectively.
Statistical analysis
If not otherwise specified, data have been reported as
mean values ± s.d. from at least three independent exper-
iments. Two-sided Student’s t test was used to analyse
differences between samples. P values <0.05 were con-
sidered statistically significant.
Results
miR-380-5p impairs the growth of DMPM cells and
inhibits TA by downregulating TEP1
To unveil possible regulators of TA in human cancer,
we focused on miR-380-5p, which was found to be
significantly under-expressed in TA-positive compared
to TA-negative DMPM tissue specimens or to normal
peritoneal specimens [5, 13] by miRNA expression
profiling (GSE99362) and subsequent validation by
real-time RT-PCR (Additional file 1: Supplementary
methods and Figure S1).
Functional studies were carried out in TA-positive
DMPM cells (STO, MP8 and MP4), which show negli-
gible endogenous levels of the miRNA compared to hu-
man normal mesothelial (MES-F) and to TA-negative,
ALT-positive cancer cells (Fig. 1b).
The ectopic expression of mature miR-380-5p (Fig. 1c;
Additional file 2: Figure S2A) induced a mild, though
significant, reduction of DMPM cell growth over time
(Fig. 1d; Additional file 2: Figure S2B), whereas it did
not impair the growth of either normal mesothelial or
telomerase-negative cancer cells (Additional file 2:
Figure S2C). miR-380-5p-mediated DMPM cell growth
impairment was associated to a remarkable inhibition of
TA (61 ± 1.7%, P < 0.01; Fig. 1e) as well as to the accu-
mulation of p53 and p21waf1 and the occurrence of
apoptosis, as revealed by the accumulation of PARP1
and Caspase-3 cleavage products and of γ-H2AX (Fig. 1f).
Moreover, miR-380-5p-dependent inhibition of TA was
paralleled by a marked decrease in the expression levels of
TEP1, which is responsible for the proper functioning of
the holoenzyme (Fig. 1a) [14]—both at mRNA and protein
level, in all three TA-positive DMPM cell lines but not in
the TA-negative U-2 Os cells (Fig. 1g, h).
To test whether the specific downregulation of TEP1
could phenocopy the effects of miR-380-5p, RNAi-
mediated depletion of TEP1 was performed in STO cells.
Specifically, cells transfected with a siRNA targeting
TEP1 (siTEP1) were characterized by a remarkable de-
crease in TEP1 mRNA and protein amounts (Fig. 2a),
which was paralleled by a pronounced inhibition of TA
(Fig. 2b) and a significant impairment of cell growth
(Fig. 2c), similarly to what was observed at the same
time point upon the reconstitution of miR-380-5p. The
evidence that the selective depletion of TEP1 reproduced
the biological effects observed in miR-380-5p-trans-
fected cells hinted at the possibility that the protein
could be a target of the miRNA.
miR-380-5p directly interacts with the open reading
frame of TEP1 and the 3′-UTR of TSPYL5
By an in silico target prediction analysis using miRWalk
2.0 [15], we found a set of genes within the list of puta-
tive miR-380-5p targets (Additional file 3: Figure S3A)
known for being involved in the maintenance of telo-
mere structure/function (e.g. POT1, TERF2, TNKS,
TNKS2) as well as in the regulation of the catalytic activ-
ity (TERT, WRAP53, PRKCA) or the expression levels
(TP53, PAX8) of telomerase. However, no miR-380-5p
binding sites were predicted within the 3′-untranslated
region (UTR) of TEP1 mRNA (Additional file 3: Figure
S3A). Moreover, western immunoblotting analyses re-
vealed that, except for a mild reduction in the amounts
of PAX8—a transcription factor that transactivates the
promoter of both TERT and TERC—none of the pre-
dicted telomere/telomerase-associated targets was found
to be downregulated upon the ectopic expression of
miR-380-5p (Additional file 3: Figure S3B).
Nonetheless, two out of five prediction tools within
miRWalk database returned the presence of putative
miRNA binding sites located within the open reading
frame (ORF) of TEP1 and two of them (i.e. site #1 and
#2 at positions 4875-4896 and 5773-5794, respectively,
GeneBank accession number NM_007110.4, Fig. 3a)
were specifically identified by RNA22 v1.0 [16]. To
check whether the two sites were recognized by miR-
380-5p, their interaction with Argonaute 2 (AGO2),
which plays a central role in miRNA-mediated RNA
silencing process [17], was examined. Such an analysis
revealed a marked enrichment for both target sequences
in miR-380-5p- with respect to preNeg-transfected cells
(Fig. 3b), with a markedly higher fold-increase for target
site #1 vs. #2. Target protection experiments were car-
ried out to further verify whether miR-380-5p-mediated
downregulation of TEP1 was consequent to the direct
miRNA-mRNA interaction at the predicted binding
sites. In particular, miR-380-5p precursor was co-
transfected with a mix of target protectors (TEP1 TPs),
namely single-stranded RNAs designed to specifically
bind the miRNA binding sites within TEP1 ORF, thus
protecting them from being targeted by miR-380-5p
(Fig. 3a). Results revealed a partial, though significant,
rescue of TEP1 protein amounts in miR-380-5p-expressing
cells in the presence with respect to the absence of TEP1
TPs (Fig. 3c). These data revealed that protection of
TEP1 ORF is sufficient to counteract, at least in part,
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the inhibitory effect of miR-380-5p and, in keeping
with target enrichment analyses, indicate that TEP1 is
indeed a direct target of the miRNA.
Furthermore, a prominent increase in p53 protein levels
was observed upon miR-380-5p reconstitution (Fig. 1f),
despite the protein has been reported to be a direct target
of the miRNA [18]. This evidence, led us hypothesizing
that other than directly targeting the ORF of TEP1, miR-
380-5p could also affect the protein function by inhibiting
the expression of one or more intermediary factors, the
downregulation of which may favour the accumulation of
p53, which in turn could impinge on TEP1 [14].
To address this issue, we paid specific attention to
testis-specific protein, Y-encoded-like 5 (TSPYL5) gene, a
member of TSPY-L family of genes [19]. The gene was
predicted by 5/5 algorithms (Additional file 3: Figure S3A)
and, according to miRWalk 2.0, bears a highly probable
(P < 0.0002) miR-380-5p binding site with a 12-nucleotide
long seed within the 3′-UTR (Fig. 3d). In keeping with this
observation, a reduction of TSPYL5 protein amounts was
appreciable in miR-380-5p expressing cells (Fig. 3e). Con-
sequently, reporter gene assays were carried out to check
if the gene could be a direct target of the miRNA. Specific-
ally, a significant and time-dependent inhibition (P < 0.01)
of reporter gene activity was observed upon the ectopic
expression of miR-380-5p in cells transfected with the
reporter construct bearing the wild-type compared to the
deleted form of TSPYL5 3′UTR (Fig. 3d, f ). Though
apparently modest, the extent of miR-380-5p-mediated in-
hibition of luciferase activity is consistent with the pres-
ence of a single predicted miRNA binding site within the
3′-UTR of the target gene [20] and suggests that TSPYL5
is amenable of targeting by the miRNA. This evidence
gained further support also by data showing that miRNA-
mediated inhibition of reporter gene activity was signifi-
cantly counteracted by the co-transfection of miR-380-5p
with LNA-380, an inhibitor of the mature form of the
miRNA (Fig. 3g).
The TSPYL5-p53 axis may act as a liaison between miR-
380-5p and TEP1
It has been recently documented that, through its
physical interaction with the ubiquitin specific protease
7, TSPYL5 leads to p53 protein level reduction and,
consequently, to the impairment of p53-target gene
regulation [19]. As such an event may have a role in
regulating TA [14, 21], we envisaged a molecular cir-
cuitry by which miR-380-5p-mediated downregulation of
TSPYL5 triggers p53 accumulation, which in turn may
impinge on TEP1 function and may result in TA inhib-
ition (Fig. 4a). The existence of such miR-380-5p-
TSPYL5-TEP1 axis was confirmed in the TA-positive
A549 cells, where the functional interplay between
TSPYL5 and p53 was firstly documented [19].
Specifically, A549 cells are characterized by barely de-
tectable levels of endogenous miR-380-5p (Fig. 1b) and,
similarly to what observed in DMPM cells, the expression
of miR-380-5p induced a significant and time-dependent
slow down of cell growth (Additional file 4: Figure S4
A-B), which was accompanied by a remarkable reduction
of TEP1 and TSPYL5 mRNA and proteins as well as by
the accumulation of p53 (Additional file 4: Figure S4C-D).
Of note, miR-380-5p failed to affect TSPYL5 RNA and
protein levels and, consequently, of p53 in the TA-
negative U-2 Os cell line (Additional file 4: Figure S4E-F),
which showed barely detectable levels of endogenous
TSPYL5 protein (Additional file 4: Figure S4E-F) compared
to TA-positive DMPM and A549 cells.
The involvement of TSPYL5 in mediating miR-380-5p
biological effects was hence explored by phenocopy exper-
iments. Specifically, a remarkable reduction of TSPYL5
mRNA and protein amounts was observed in both STO
Fig. 2 RNAi-mediated depletion of TEP1 recapitulates the biological effects of miR-380-5p. a TEP1 mRNA expression levels (upper panel) and
protein amounts (lower panel) in STO cells assessed 72 h after the transfection with the indicated siRNAs. Data have been reported as RQ (mean
values ± s.d.) in siCTR and siTEP1-transfected vs. NT cells; ***P < 0.001 vs. siCTR-transfected cells. b Relative TA in siCTR and siTEP1-transfected STO
vs. NT cells (mean values ± s.d.); ***P < 0.001 vs. siCTR-transfected cells. c STO cell growth assessed 72 h after siRNA-mediated depletion of TEP1
(number of growing NT, siCTR- and siTEP1-transfected cells; mean values ± s.d.); **P < 0.01 vs. siCTR-transfected cells
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Fig. 3 miR-380-5p directly targets the ORF of TEP1 and the 3′-UTR of TSPYL5. a Schematic representation of the interaction between miR-380-5p and
its predicted TEP1 binding sites. TEP1 sequences used to design target protectors are also shown. Numbers in brackets indicate the nucleotide position
within TEP1 mRNA (NM_007110.4). b Representative RT-PCR showing miR-380-5p target site enrichment. Input: total RNA in cell lysates, AGO2- and
IgG-IP: RNA isolated from AGO2- and IgG-immunoprecipitated samples. The graph on the bottom shows TEP1 mRNA enrichment quantification
reported as fold-enrichment (mean values ± s.d.) in the indicated immunoprecipitated samples with respect to IgG-IP from NT cells; **P < 0.01.
c Representative immunobloting showing TEP1 amounts in preNeg- and miR-380-5p-transfected cells ± target protectors. Cropped images of selected
proteins are shown. The graph on the bottom shows the quantification of TEP1 protein (relative amounts with respect to preNeg-transfected cells;
mean values ± s.d.); **P < 0.01 vs. miR-380-5p-transfected cells. d Schematic representation of the interaction between miR-380-5p and its predicted
binding site within TSPYL5 3′-UTR (NM_033512.2). The mutated sequence (del43-54) bearing a deletion corresponding to miR-380-5p seed and the
sequence within TSPYL5 3′UTR used to design the target protector are also shown. (e) Representative immunoblotting showing TSPYL5 amounts in
miR-380-5p expressing STO cells. Cropped images of selected proteins are shown. f Time-course assessment of luciferase activity in cells transfected
with the wild-type or mutated (del43-54) reporter constructs in the presence of miR-380-5p (percentage of luciferase activity inhibition in miR-380-5p
vs. preNeg-transfected cells; mean values ± s.d.); **P < 0.01 TSPYL5 3’UTRwt vs. TSPYL5 3’UTR del43-54. g Assessment of luciferase activity as a function
of the different combinations of transfected oligomers. Data have been reported as Gluc/SEAP activity ratio (mean values ± s.d.); *P < 0.05; **P < 0.01 vs.
pEX-MT05-transfected cells. Numbers under the X-axis indicate the percent reduction (−) or increase (+) of luciferase activity vs. pEX-MT05-expressing
cells. Asterisk in bracket indicates the level of statistical significance (P < 0.05) between LNA380/miR-380-5p and LNANeg/miR-380-5p samples
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and A549 cells after the transfection with a siRNA
targeting TSPYL5 (siTSPYL5) (Fig. 4b, c). In addition,
the selective depletion of TSPYL5 led to p53 accumula-
tion and, similarly to what observed upon miR-380-5p
reconstitution, to TEP1 protein reduction and TA
inhibition (Fig. 4c, d). This evidence indicates that the
depletion of TSPYL5 and the consequent accumulation
of p53 may contribute, at least in part, to the direct
effect of the miRNA on TEP1. In fact, we found that
the inhibitory effect on TEP1 expression levels exerted
by the miRNA was partly counteracted by the selective
depletion of p53 (Additional file 4: Figure S4C and G).
In addition, TSPYL5 target protection counteracted the
inhibitory effect of miR-380-5p on the target and
resulted in a reduced accumulation of p53 and in a rescue,
though partial, of TEP1 protein amounts (Additional file 4:
Figure S4 H and I).
The causative role of p53 in the regulation of TEP1
levels gained further support by the evidence that the
remarkable accumulation of p53 caused by the exposure
of STO and A549 cells to doxorubicin was accompanied
by a dramatic reduction of TEP1 protein amounts
(Fig. 4e), which instead were not remarkably affected
upon silencing of p53 (Fig. 4e). These observations
indicate that p53 may be actually involved in the control
of TEP1 expression, as also suggested by the finding that
doxorubicin induced a significant down-modulation of
TEP1 mRNA levels in p53-proficient STO and A549
cells (Fig. 4f ).
Long-term miR-380-5p transfectants exhibit features
reminiscent of ALT
In accordance with the paradigm that a lag period is re-
quired to induce sufficient telomere shortening to impair
Fig. 4 The TSPYL5-p53 axis may act as a liaison between miR-380-5p and TEP1. a Schematic representation of the proposed molecular circuitry
by which miR-380-5p may interfere with TEP1 expression/function in cancer cells. Other than directly acting on the ORF of TEP1, miR-380-5p may interfere
with the gene expression/function via a TSPYL5-p53 axis. It is possible to hypothesize that p53 may impinge on TEP1 levels by (1) transcriptional repression,
(2) increased degradation and/or (3) physical interaction (sequestration). Ub ubiquitin. b Assessment of TSPYL5 expression levels in STO and A549 cells
transfected with siCTR or siTSPYL5 (RQ in transfected vs. NT cells; mean values ± s.d.); **P < 0.01 vs. siCTR-transfected cells. c Representative
immunoblottings showing TSPYL5, TEP1 and p53 protein amounts in NT, siCTR- and siTSPYL5-transfected cells. Cropped images of selected
proteins are shown. d Quantification of TA in siCTR- and siTSPYL5-transfected cells (arbitrary units (au.); mean values ± s.d.); *P < 0.05;**P < 0.01 vs.
siCTR-transfected cells. e Representative immunoblottings showing TEP1 and p53 protein amounts in STO and A549 cells as a function of the indicated
treatment modalities. Cropped images of selected proteins are shown. The graph on the right shows the quantification of protein amounts reported
as percentage (mean values ± s.d.) with respect to untreated cells (i.e. no siRNAs and no doxorubicin). f Assessment of TEP1 mRNA expression levels in
STO and A549 cells in the absence or presence of doxorubicin (RQ in doxorubicin-treated vs. untreated cells; mean values ± s.d.); *P < 0.05 ***P < 0.001
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cancer cell growth in the presence of inhibited TA
[7], long-term reconstitution of miR-380-5p was pur-
sued. Similarly to what observed in the short-term
setting, after 3 months of weakly reiterated transfec-
tions with miR-380-5p, STO cells showed high levels
of mature miR-380-5p (Fig. 5a) as well as a remark-
able decrease in TEP1 mRNA expression levels and
TA inhibition (Fig. 5b). Nevertheless, no evident telo-
mere exhaustion was appreciable over this period of
time (Table 1). Contrarily, upon 3 months of persist-
ent reconstitution of miR-380-5p, a slight but signifi-
cant increase in mean telomere length (about +1 Kb)
was observed (Table 1). In addition, long-term miR-
380-5p transfectants showed a significant reduction in
the expression levels of ATRX (Fig. 5c) as well as de-
tectable levels of C-circle DNA (Fig. 5d), two molecu-
lar markers associated with ALT activity [2, 22]. In
addition, long-term STO cells expressing miR-380-5p
were characterized by altered growing properties, in
that compared to preNeg-transfected cells, they preva-
lently formed clusters with a remarkable component
of vertical growth (Fig. 5e). However, despite these al-
terations in the growing properties, no growth arrest
or massive culture loss was observed over the 3-
month period of miR-380-5p reconstitution. Instead,
miR-380-5p-expressing cells continued to grow in cul-
ture, though at significantly reduced rate compared to
control cells (Fig. 5f ).
Discussion
In the present study, we reported that the ectopic
reconstitution of miR-380-5p in DMPM cells with
active telomerase and negligible levels of endogen-
ous miRNA results in TA inhibition and in cell
growth impairment. We documented for the first
time that such an effect was the result of a molecu-
lar circuitry converging on TEP1, where the miRNA
was able to target it directly within the ORF and
indirectly via TSPYL5 down-modulation and p53
accumulation.
The evidence that miR-380-5p may reasonably play
a role in regulating TA via a TSPYL5-p53 axis, other
than by directly targeting TEP1, gains support by
early evidence showing that p53 may repress telomer-
ase by interacting with TEP1 and preventing it from
correctly assembly with the holoenzyme [14]. In
addition, the over-expression of wild-type p53 has
been shown to inhibit TA in several cancer cell lines
by causing TERT transcriptional repression through
an indirect mechanism involving p21waf1 [21], which
indeed accumulated in cells ectopically expressing
miR-380-5p (Fig. 1f ). In keeping with our findings is
the evidence that telomerase reactivation during
cancer cell immortalization may occur through the
impairment of the p53-p21waf1 pathway caused by the
overexpression of miR-296, which was found up-
regulated in telomerase-positive cancer cells [23] as
well as that miR-375-mediated suppression of mul-
tiple oncogenic factors resulted in TA inhibition as a
consequence of p53-p21waf1 accumulation in HPV-
associated cancer cells [24]. These findings are in
keeping with recent observations showing that the se-
lective depletion of TSPYL5 in A549 cells resulted in
a marked accumulation of p21waf1 associated with a
reduced activation of the PI3K/AKT cell growth/sur-
vival pathway [25] and that the ectopic expression of
TSPYL5 prevented the cell growth arrest induced by
the acute overexperession of RASV12 in TERT-
immortalized human diploid fibroblast selectively de-
pleted for p16INK4a [19].
Our findings also showed that long-term miR-380-
5p transfectants, despite characterized by a remark-
able downregulation of TEP1 expression levels and
TA inhibition, did not undergo telomere attrition.
Oppositely, these cells, which continued to grow in
cultures though at slower rate compared to parental
cells, where characterized by reduced expression of
ATRX and by the appearance of C-circle DNA, two
molecular features usually associated with ALT
activity [2].
This event is anything but trivial. In fact, telomerase
is activated in the great majority of human cancers [7],
including DMPM [5], and Imetelstat has been the first
inhibitor of telomerase catalytic activity to enter clinical
trials for different malignancies [26]. In addition, other
than being activated in a subset of human tumours with
no detectable TA, ALT may co-exist with telomerase
due to intratumoural heterogeneity or the spontaneous
activation of both TMM within the same tumour cells
[1]. Consequently, treatment of these tumours with
telomerase inhibitors could favour the clonal expansion
of ALT cell subpopulations that will be refractory to
anti-telomerase therapies. Moreover, it is plausible to
hypothesize that ALT, which may be considered a less
readily controllable TMM compared to telomerase
[27], may likely emerge in telomerase-positive tu-
mours upon prolonged exposure to enzyme inhibitors,
hence representing a threat to the clinical efficacy of
this class of therapeutic agents. Even if such a hy-
pothesis has not been confirmed in the clinical setting
yet, it gains support by preclinical evidence showing
that T-cell lymphomas arising in telomerase knocked-
out mice enter a period of slow growth and then
emerge with ALT features [28]. Moreover, it has been
observed that laryngeal cancer cells depleted for
TERT continue to proliferate in culture, though at
slower rate compared to parental cells, despite a
marked inhibition of TA, and, after 30 population
Cimino-Reale et al. Journal of Hematology & Oncology  (2017) 10:140 Page 10 of 14
doublings, show a significantly higher mean telomere
length associated with evidence of ALT [29]. In
addition, the RNAi-mediated co-depletion of histone
chaperone anti-silencing factors 1a and 1b in TERT-
immortalized lung fibroblasts and in a sub-line of
HeLa cells characterized by long telomeres resulted in
TA inhibition and the concomitant appearance of
ALT-associated hallmarks [30].
Fig. 5 miR-380-5p mixes up the phenotype of DMPM cells. a Assessment of miR-380-5p expression levels upon weakly transfection of STO cells with preNeg
or miR-380-5p precursor (Log10(RQ) with respect to NT cells; mean values ± s.d.). b Quantification of TEP1 mRNA levels and of TA in
miR-380-5p expressing cells at month 3. Data have been reported as percentage inhibition (mean values ± s.d.) in miR-380-5p- vs. preNeg-
transfected cells. c Assessment of ATRX expression levels (RQ in preNeg- and miR-380-5p-transfected vs. NT cells; mean values ± s.d.);
**P < 0.01 for miR-380-5p vs. preNeg. d Quantification of C-circle DNA levels in preNeg- and miR-380-5p-transfected cells at the indicated
time points (percentage of c-circle DNA levels in each sample with respect to U-2 Os cells; mean values ± s.d.); HeLa: negative control; *P < 0.05 for
miR-380-5p vs. preNeg at month 3. e Representative photomicrographs showing the morphology of preNeg- and miR-380-5p-transfected STO
cells. Original magnification: ×4; Scale bar: 100 μm. f Growth curves of NT, preNeg- and miR-380-5p-transfected STO cells. Data have been
reported as cumulative number of growing cells over a 3-month period. The level of statistical significance for the comparison between
preNeg and miR-380-5p groups has been assessed by two-way ANOVA
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Conclusions
The comprehension of the molecular and cellular features
of DMPM is of utmost importance for the fruitful man-
agement of the disease, especially in patients who fail
standard treatments and have a poor prognosis due to the
lack of effective alternative therapeutic options [31, 32]. In
this context, TMM have been proposed to represent a res-
ervoir of candidate targets for the development of novel
therapeutic interventions for the disease [32].
Limited information is currently available on the func-
tional role of specific miRNAs in DMPM [13], and a
handful of miRNAs have been identified thus far for hav-
ing a role in the regulation of telomere maintenance in
cancer [1, 23, 24, 33–36]. Here, we have provided evi-
dence that miR-380-5p may interfere with TA and leads
to cell growth impairment and induction of apoptosis in
relevant models of DMPM. In addition, we have shown
that long-term ectopic reconstitution of miR-380-5p
leads to the emergence of cells with features that, at least
in part, are reminiscent of an ALT phenotype (that here
we refer to as “ALT-like”) that could provide DMPM
cells with a compensatory mechanism to ensure con-
tinuous cell growth even in a context of partially inhib-
ited TA. This observation deals with a major clinical
challenge that telomerase-based therapeutic agents have
to face, that is the need of a continuous, long lasting
treatment to achieve clinically relevant therapeutic
responses [7]. This may in turn results in toxicities
which would require off treatment periods (hence loss of
achieved benefits) and/or in the emergence of subpopu-
lations of “ALT-reverting” cells that do not respond
anymore to telomerase inhibitors.
A genome-wide analysis of the molecular alterations
occurring in DMPM cells upon the long-term restoration
of miR-380-5p could be instrumental for the identification
of specific factors responsible for the emergence of the
“ALT-like” phenotype to be validated as therapeutic tar-
gets. This information may hence furnish the biological
rationale for the development of novel therapeutic
interventions not only to be used in combination with
inhibitors of the canonical function of telomerase in
TA-positive tumours [37] but also to be tested in
ALT-naïve tumour models.
Additional files
Additional file 1: Figure S1. miR-380-5p is significantly under-
expressed in telomerase-positive DMPM tissue specimens. Description of
data: (A) miR-380-5p endogenous expression levels assessed by miRNA
expression profiling. Data have been reported as log2-transformed
normalized signal intensities for miR-380-5p in each specimen. Horizontal
lines represent the mean values of miR-380-5p expression levels in each
group (normal vs. TA-positive vs. TA-negative specimens). (B) Real-time
RT-PCR validation of endogenous miR-380-5p expression levels in normal
samples, in TA-positive and TA-negative DMPM tissue specimens. Data
have been reported as Log10(RQ) (mean values ± s.d.) with respect to the
average miRNA expression levels detected in normal samples, using the 2
−ΔΔCt method. **P < 0.01 vs. TA-negative specimens. (PDF 72 kb)
Additional file 2: Figure S2. miR-380-5p impairs the growth of DMPM
cells. Description of data: (A) Time-course assessment of miR-380-5p
expression levels in preNeg- and miR-380-5p-transfected MP8 and MP4
cells (Log10(RQ) with respect to NT cells; mean values ± s.d.). (B) Growth
curves of NT, preNeg- and miR-380-5p-transfected MP8 and MP4 cells
(number of growing cells; mean values ± s.d.); *P < 0.05; **P < 0.02 miR-
380-5p vs. preNeg. (C) Assessment of miR-380-5p expression levels (white
bars) and cell growth (black bars) after a 96-h transfection of MES-F and
U-2 Os cells with preNeg or miR-380-5p precursor. Data have been
reported as Log10(RQ) for miRNA expression levels (left Y-axis) and as the
percentage of growing cells (right Y-axis) with respect to NT cells (mean
values ± s.d.). (TIF 1087 kb)
Additional file 3: Figure S3. In silico prediction analysis of putative
miR-380-5p target genes by miRWalk 2.0. Description of data: (A) By the
predicted target module of miRWalk 2.0—a comprehensive database that
provides indications on predicted and validated binding sites on miRNA
target genes [14]—we obtained a combined information on putative
miR-380-5p binding sites within the 3′UTRs of human RefSeq mRNAs in
terms of union of the predictions generated by five distinct algorithms
(i.e. miRWalk 2.0; miRanda-rel2010; miRMap; RNA22v2 and Targetscan6.2).
(B) Representative western immunoblotting showing the amounts of
protein encoded by predicted miR-380-5p target genes in STO cells
transfected with preNeg or miR-380-5p. Target proteins have been
selected among those known to play a role in TMM and reported in
panel A. Cropped images of selected proteins are shown. (TIF 432 kb)
Additional file 4: Figure S4. Effects of miR-380-5p reconstitution on
A549 lung adenocarcinoma cells. Description of data: (A) Assessment of
miR-380-5p expression levels in preNeg and miR-380-5p-transfected cells
(Log10(RQ) vs. NT cells; mean values ± s.d.). (B) Growth curves of NT,
preNeg- and miR-380-5p-transfected cells (number of growing cells;
mean values ± s.d.); **P < 0.02. (C) Assessment of TEP1 (black bars) and
TSPYL5 (white bars) mRNA expression levels in p53 proficient (siCTR) and
p53-depleted (sip53) cells ectopically expressing miR-380-5p (Log10(RQ)
vs. NT cells; mean values ± s.d.); *P < 0.05 vs. siCTR-transfected cells. (D)
Representative immunoblotting showing TSPYL5, TEP1 and p53 protein
amounts in NT, preNeg- and miR-380-5p-transfected A549 cells. Cropped
images of selected proteins are shown. (E) Assessment of TSPYL5 mRNA
expression levels in preNeg- and miR-380-5p-transfected U-2 Os cells (RQ
vs. NT cells; mean values ± s.d.). (F) Representative immunoblotting
showing TSPYL5 and p53 protein amounts in NT, preNeg- and miR-380-
5p-transfected U-2 Os cells. Cropped images of selected proteins are
shown. (G) Representative immunoblotting showing p53, TEP1 and
TSPYL5 protein levels in p53 proficient (siCTR) and p53-depleted (sip53)
cells ectopically expressing miR-380-5p. Cropped images of selected
proteins are shown. The graph on the right shows the quantification of
TEP1 (black bars) and TSPYL5 (white bars) protein amounts as a function
of the different transfected oligomers (relative quantity vs. NT cells; mean
values ± s.d.); *P < 0.05 vs. siCTR-transfected cells. (H) Representative
immunobloting showing TSPYL5, p53 and TEP1 amounts in preNeg- and
miR-380-5p-transfected cells ± target protector (TSPYL5 TP). Cropped
images of selected proteins are shown. (I) Quantification of TSPYL5 (white
bars), TEP1 (black bars) and p53 (grey bars) protein amounts in preNeg-
and miR-380-5p-transfected cells ± TSPYL5 TP (relative amounts with
respect to preNeg-transfected cells; mean values ± s.d.); **P < 0.01 vs.
miR-380-5p-transfected cells. (TIF 1515 kb)
Table 1 Quantification of mean telomere length (mTL) in STO
cells transfected with preNeg or miR-380-5p
mTL (Kb) week 1 mTL (Kb) month 3 Pa
preNeg 3.35 ± 0.17 3.50 ± 0.20 n.s.
miR-380-5p 3.29 ± 0.15 4.28 ± 0.30 <0.005
Pb n.s. P < 0.01
n.s not significant
amonth 3 vs. week 1
bmiR-380-5p vs. preNeg (Student’s t-test)
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